Breaking News Instant updates and real-time market news.

IDXX

Idexx Laboratories

$162.05

4.24 (2.69%)

, ZTS

Zoetis

$72.79

0.69 (0.96%)

10:55
01/04/18
01/04
10:55
01/04/18
10:55

Stifel medical tech & supplies analyst holds analyst/industry conference call

Medical Technology & Supplies Analyst Block discuss the outlook for 2018, as well as near-term catalysts and sentiment for the Medical Technology & Supplies Industry including IDEXX, Zoetis, Dentsply, Align Technology, Glaukos, Trupanion, Abaxis, Sientra and Hologic on an Analyst/Industry conference call to be held on January 4 at 11 am.

IDXX

Idexx Laboratories

$162.05

4.24 (2.69%)

ZTS

Zoetis

$72.79

0.69 (0.96%)

XRAY

Dentsply Sirona

$66.91

-0.23 (-0.34%)

ALGN

Align Technology

$231.20

6.58 (2.93%)

HOLX

Hologic

$43.49

0.62 (1.45%)

GKOS

Glaukos

$26.14

-1.03 (-3.79%)

TRUP

Trupanion

$29.63

0.69 (2.38%)

ABAX

Abaxis

$49.52

-0.48 (-0.96%)

SIEN

Sientra

$14.03

-0.24 (-1.68%)

  • 04

    Jan

  • 30

    Jan

  • 15

    Feb

  • 26

    Feb

IDXX Idexx Laboratories
$162.05

4.24 (2.69%)

07/28/17
KING
07/28/17
UPGRADE
KING
Buy
IDEXX upgraded to Buy from Neutral at CL King
08/23/17
08/23/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Rockwell Collins (COL) upgraded to Buy from Hold at Vertical Research by analyst Robert Stoddard, as he believes there remains the possibility of the company being acquired. As detailed in colleague Jeff Sprague's related report United Technologies (UTX), the two analysts cannot rule out United Technologies making a bid for Rockwell Collins. They believe it could be more exotically structured as a Reverse Morris Trust, which would make a transaction more financially appealing to United Technologies shareholders, while preserving its credit rating, and providing Rockwell Collins shareholder with a decent premium. 2. JD.com (JD) upgraded to Buy from Hold at MKM Partners by analyst Rob Sanderson based on valuation and his belief that Chinese e-commerce is powerful enough to support "a strong number two," while the company's "position" is "sustainably differentiated." 3. IDEXX (IDXX) upgraded to Buy from Neutral at BofA/Merrill by analyst Derik De Bruin, who said new data supports 10% long-term organic revenue and 15%-20% earnings CAGRs through 2022 driven by higher diagnostic utilization by the installed base, new product ramps, and further innovation. The analyst said the pullback since the solid Q2 report provides a buying opportunity for this "top dog." 4. Intuit (INTU) upgraded to Equal-Weight from Underweight at First Analysis by analyst James Macdonald, who raised his price target to $128 from $102 following the "strong" quarter and better than expected 2018 guidance driven by Small Business growth. 5. G-III Apparel (GIII) upgraded to Overweight from Neutral at Piper Jaffray by analyst Erinn Murphy to reflect the recent pullback in shares and maintained a $27 price target. The analyst expects wholesale trends to "fuel upside" and believes the new DKNY product is checking well at retail. To see The Fly's full Street Research coverage, click here.
01/03/18
ADAM
01/03/18
NO CHANGE
ADAM
Canaccord names Illumina among top 2018 picks in Diagnostics and Tools industry
Canaccord analyst Mark Massaro rolled out his top 2018 picks in the Diagnostics and Tools segment after noting his 2017 picks returned 38% overall. He said he prefers larger companies in 2018 and said Illumina (ILMN) is a must own here due to its continued market dominance. The analyst raised his price target to $255 from $235 on Illumina shares. The analyst also recommends Exact Sciences (EXAS) as he expects its strong growth to continue. Massaro reiterated his $60 price target on Exact Sciences shares. He also likes Hologic (HOLX) and expects 2018 to be a bounce back year, raising his price target to $50 from $44. The analyst also likes Lab Corp. (LH) and believes it is likely to see an earnings acceleration and multiple expansion. He raised his price target to $190 from $175 on Lab Corp. shares. Finally, Massaro likes IDEXX (IDXX) for its new product launches and underlying global trends, keeping a $180 price target on the shares.
08/23/17
BOFA
08/23/17
UPGRADE
Target $175
BOFA
Buy
IDEXX upgraded to Buy from Neutral at BofA/Merrill
BofA/Merrill analyst Derik De Bruin upgraded IDEXX to Buy from Neutral and maintained a $175 price target following last week's Analyst Day. The analyst said new data supports 10% long-term organic revenue and 15%-20% earnings CAGRs through 2022 driven by higher diagnostic utilization by the installed base, new product ramps, and further innovation. The analyst said the pullback since the solid Q2 report provides a buying opportunity for this "top dog."
ZTS Zoetis
$72.79

0.69 (0.96%)

12/14/17
HDLY
12/14/17
NO CHANGE
HDLY
Hilliard Lyons Top Ideas for Year-End 2017
Hilliard Lyons Research named its Top Ideas for Year-End 2017. They are: Pinnacle Financial (PNFP), Disney (DIS), J.M. Smucker (SJM), NextEra Energy (NEE), Zoetis (ZTS), Leggett & Platt (LEG), South Jersey Industries (SJI), Tanger Factory (SKT), Physicians Realty Trust (DOC), VMware (VMW), AT&T (T), and American Water (AWK).
01/04/18
SBSH
01/04/18
UPGRADE
Target $85
SBSH
Buy
Zoetis upgraded to Buy from Neutral at Citi
Citi analyst Liav Abraham upgraded Zoetis (ZTS) to Buy and raised her price target for the shares to $85 from $67. The analyst "more constructive" on the Specialty Pharma group heading into 2018. More realistic expectations, along with pipeline catalysts set the stage for a potential inflection point for some of the stocks in 2018, Abraham tells investors in a research note on the sector. She expects continued commercial execution across Zoetis' portfolio and sees potential for continued topline growth in 2018. Mylan (MYL) is Abraham's top pick for 2018.
01/02/18
CHLM
01/02/18
NO CHANGE
Target $85
CHLM
Buy
Zoetis price target raised to $85 from $77 at Craig-Hallum
Craig-Hallum analyst Kevin Ellich raised his price target for Zoetis to $85 from $77 as he believes colder temperatures instill confidence in sales of premium products and revenue projections. The analyst reiterates a Buy rating on the shares.
12/22/17
CANT
12/22/17
NO CHANGE
CANT
Cantor ups price targets for Teva, Valeant, Mylan, Zoetis
Cantor Fitzgerald analyst Louise Chen raised her price target for Neutral-rated Teva (TEVA) to $18 from $10, for Overweight-rated Valeant (VRX) to $25 from $23, for Neutral-Mylan (MYL) to $41 from $34 and for Overweight-rated Zoetis (ZTS) to $85 from $80. Heading into 2018, the analyst believes Perrigo (PRGO) has the best setup in the Specialty Pharmaceuticals space. The company has given the most visibility on its outlook for 2018, Chen tells investors in a research note. She believes Zoetis, Mylan and Horizon Pharma (HZNP) also look good into next year.
XRAY Dentsply Sirona
$66.91

-0.23 (-0.34%)

12/13/17
JPMS
12/13/17
UPGRADE
Target $75
JPMS
Overweight
Dentsply Sirona upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Tycho Peterson upgraded Dentsply Sirona to Overweight and raised his price target for the shares to $75 from $65. The dental equipment maker closed yesterday down 3c to $64.99. The analyst expects "meaningful improvement" to the company's organic growth in 2018, although he notes management's initial guidance will likely be conservative. Peterson sees 2018 being marked by "beat-and-raise" quarters. Dental remains a "reasonably attractive and stable" market and Dentsply's new management has a "significant opportunity" to create value through margin expansion and capital deployment, the analyst tells investors in a research note.
12/13/17
12/13/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Huntsman (HUN) reinstated with an Overweight from Neutral at JPMorgan with analyst Jeffrey Zekauskas saying a strengthened balance sheet from asset sales, "healthy" Urethane Chemical business conditions and good free cash flow generation bring a favorable risk/reward. 2. Dentsply Sirona (XRAY) upgraded to Overweight from Neutral at JPMorgan with analyst Tycho Peterson saying he expects "meaningful improvement" to the company's organic growth in 2018, although he notes management's initial guidance will likely be conservative. 3. O'Reilly Automotive (ORLY) upgraded to Outperform from Sector Perform at RBC Capital with analyst Scot Ciccarelli saying that despite the 15% run-up in stock price last month, 2018 set-up remains favorable with building demand from mild weather, easing comps headwinds, and an attractive relative valuation. 4. Extra Space Storage (EXR) upgraded to Equal Weight at Morgan Stanley with analyst Richard Hill saying he expects relatively less deceleration of core growth in the fourth quarter and for its 2018 guidance to be in line with expectations. He raised his price target on Extra Space Storage to $83 from $70. 5. Taubman Centers (TCO) upgraded to Market Perform from Underperform at BMO Capital with analyst R. Jeremy Metz saying M&A activity, activist involvement, and speculation will keep shares supported in the near-term despite the challenging environment. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/08/17
DBAB
12/08/17
INITIATION
Target $81
DBAB
Buy
Dentsply Sirona initiated with a Buy at Deutsche Bank
Deutsche Bank analyst Glen Santangelo started Dentsply Sirona with a Buy rating and $81 price target. New management is "breathing new life into the company," and a more aggressive integration/cost discipline strategy is going to translate into an inflection in earnings growth, the analyst contends.
12/19/17
DBAB
12/19/17
NO CHANGE
Target $79
DBAB
Buy
Deutsche Bank survey finds dentists mixed on Amazon
Deutsche Bank analyst Glen Santangelo says his firm's survey of 81 dentists "somewhat supports" the view that dentists are not overly convinced that purchasing consumables online is the obvious choice for their practice. The analyst does not believe the "near-term reality matches the current level of fear" regarding competition from Amazon (AMZN). The threat of Amazon and the potential for increased online competition has weighed on sentiment of Henry Schein (HSIC) over the last few months, Santangelo tells investors in a research note. He points out the stock is down 7% for the year after declining 4% in 2016. Santangelo believes Henry Schein has the potential to see a rebound in both consumable and equipment growth, creating an attractive risk/reward for the stock heading into 2018. The analyst keeps a Buy rating on the shares with a $79 price target. Other names in the dental supply space include Patterson Companies (PDCO) and Dentsply Sirona (XRAY).
ALGN Align Technology
$231.20

6.58 (2.93%)

12/08/17
DBAB
12/08/17
INITIATION
Target $250
DBAB
Hold
Align Technology initiated with a Hold at Deutsche Bank
Deutsche Bank analyst Glen Santangelo started Align Technology with a Hold rating and $250 price target. The analyst cites valuation for his Hold rating.
11/27/17
MSCO
11/27/17
NO CHANGE
Target $300
MSCO
Overweight
Align Technology price target raised to $300 from $257 at Morgan Stanley
Morgan Stanley analyst Steve Beuchaw raised his price target on Align Technology to $300 from $257 as he estimates that the company can capture 50% of an about 400,000 case at-home orthodontic market in the U.S. Pilots of storefront and the coming launch of "Invisalign Go" demonstrate the company's commitment to the at-home orthodontic market, said Beuchaw, who keeps an Overweight rating on Align shares.
12/04/17
LEER
12/04/17
NO CHANGE
LEER
Outperform
Leerink says Align Technology selloff a buying opportunity
Leerink analyst Richard Newitter said he suspects that Align Technology's underperformance today compared to the medical technology space is due to worries about competition after the CEO voiced that more of it is coming in 2018. However, this is nothing new and "nebulous stock moves on competition fears" will prove to be a buying opportunity, Newitter tells investors. The analyst, who said he came out of the recent meetings with company management more bullish on its near-term and long-term adoption prospects, reiterates an Outperform rating on Align Technology shares, which are down 9% to $231.05 in afternoon trading.
11/28/17
FBCO
11/28/17
NO CHANGE
Target $276
FBCO
Outperform
Align Technology price target raised to $276 from $261 at Credit Suisse
Credit Suisse analyst Erin Wilson Wright raised her price target for Align Technology to $276 from $261 saying there continues to be no end in sight for the company's "torrid growth," as management detailed DTC initiatives and financing programs that should fuel market traction among patients and practitioners, underappreciated dynamics. The analyst reiterates an Outperform rating on the shares.
HOLX Hologic
$43.49

0.62 (1.45%)

12/27/17
GSCO
12/27/17
NO CHANGE
GSCO
Conviction Buy
Hologic positioned to outperform in 2018, says Goldman Sachs
Goldman analyst Isaac Ro believes Conviction Buy rated Hologic is well positioned to outperform the peer group in 2018 following 2017 underperformance. The analyst sees renewed management focus and stability, which should have a positive impact on the business and investor sentiment. Ro thinks Cynosure expectations have been sufficiently reset following the most recent earnings call and the core business should see a modest boost from product cycles and tax reform.
01/03/18
EVER
01/03/18
INITIATION
Target $50
EVER
Outperform
Hologic initiated with an Outperform at Evercore ISI
Evercore ISI analyst Vijay Kumar started Hologic with an Outperform rating and $50 price target. The analyst believes management can turnaround the business and finds expectations low at at current share levels.
01/04/18
BOFA
01/04/18
UPGRADE
Target $50
BOFA
Buy
Hologic upgraded to Buy from Neutral at BofA/Merrill
BofA/Merrill analyst Derik De Bruin upgraded Hologic (HOLX) to Buy from Neutral and increased its price target to $50 from $42. The analyst was cautious on Hologic's acquisition of CynoSure (CYNO) last February and still sees risk in Q1, but said comps get easier for the rest of FY18 and expects shares to move higher if CynoSure rebounds. Further, the analyst said Hologic's core business is solid with potential upside, sees benefits from tax reform, views valuation as attractive, and expects the multiple to trend back to Med Tech peer levels.
GKOS Glaukos
$26.14

-1.03 (-3.79%)

12/28/17
CANT
12/28/17
NO CHANGE
Target $48
CANT
Overweight
Glaukos price target lowered to $48 from $60 at Cantor Fitzgerald
Cantor Fitzgerald analyst Elemer Piros lowered his price target for Glaukos to $48 following a model refresh heading into 2018. The anlayst, however, reiterates an Overweight rating on the shares following the company's iStent Inject device pre-market approval application filing with the FDA. While questions over competition and reimbursement dominated the last few quarters, the headwinds are manageable and investors underappreciate the long-term potential of the iStent franchise, Piros tells investors in a research note.
12/12/17
WELS
12/12/17
NO CHANGE
Target $42
WELS
Outperform
Reimbursement remains favorable for Glaukos iStent, says Wells Fargo
After Medicare administrative contractors Palmetto and Cahaba posted their 2018 physician fee schedules for Glaukos' iStent and Alcon's CyPass, Wells Fargo analyst Larry Biegelsen notes that the 2018 rates represent a meaningful cut to iStent physician reimbursement versus 2017 rates and signal a potential continued trend of physician reimbursement cuts from the different MACs. Still even at these lower rates iStent procedures remain very profitable, the analyst argues, adding that adoption should not be meaningfully impacted by these cuts. He reiterates an Outperform rating and $42 price target on Glaukos' shares.
12/11/17
PIPR
12/11/17
NO CHANGE
Target $35
PIPR
Overweight
Piper sees 'another incremental headwind' for Glaukos, stays Overweight
Medicare Administrative Contractor Palmetto posted updated micro invasive glaucoma surgery fees starting January 7, 2018, with cuts to the CPT code for physicians down to $308 from closer to $800-$900 before, Piper Jaffray analyst Matt O'Brien tells investors in a research note. He believes this move was relatively expected by the Street. However, the analyst notes that CyPass, a competitive stent from Alcon, received a code from Palmetto that is $100 higher. He views this news as a "major curve ball" for Glaukos investors. Further, another Medicare Administrative Contractor, Cahaba, lowered its physician fee rate to $412 but kept CyPass and iStent reimbursement the same, O'Brien writes. Taken together, today's developments are "another incremental headwind" for Glaukos which will likely dampen utilization rates, the analyst contends. He believes, though, that the company's iStent is a better product than CyPass and that there is "plenty of opportunity for growth." O'Brien recommends "risk tolerant" investors take advantage of today's pullback in Glaukos shares. He has an Overweight rating on the name with a $35 price target.
12/28/17
WELS
12/28/17
NO CHANGE
WELS
Outperform
Glaukos iStent inject device to reaccelerate growth, says Wells Fargo
Wells Fargo analyst Larry Biegelsen yesterday reiterated his belief that the U.S. launch of iStent inject will reaccelerate Glaukos' top line growth. The company yesterday announced that it has submitted a pre-market approval application to the FDA for the iStent inject Trabecular Micro-Bypass Stent. The analyst currently models for Glaukos worldwide sales growth of 9.2% in 2018, improving to 21.4% in 2019. Based on his channel checks, iStent inject offers clinicians with increased efficacy over the first-generation iStent product and increased ease of use. Biegelsen believes that iStent inject is the easiest of any of the microinvasive glaucoma surgery devices to implant. He keeps an Outperform rating on Glaukos.
TRUP Trupanion
$29.63

0.69 (2.38%)

11/21/17
KING
11/21/17
INITIATION
KING
Neutral
Trupanion initiated with a Neutral at CL King
CL King analyst David Westenberg initiated Trupanion with a Neutral saying shares need to "breath" given "stretched" valuation.
10/31/17
ADAM
10/31/17
NO CHANGE
Target $35
ADAM
Buy
Trupanion price target raised to $35 from $29 at Canaccord
Canaccord analyst Michael Graham raised his price target on Trupanion to $35 from $29 heading into Q3 results. The analyst refreshed his model to better reflect the company's ongoing focus on internal rate of return and he believes it should justify more marketing dollars, which will pave the way for top-line growth rates to remain high for several years. Graham reiterated his Buy rating on Trupanion shares.
ABAX Abaxis
$49.52

-0.48 (-0.96%)

06/09/17
AGIS
06/09/17
INITIATION
Target $56.5
AGIS
Hold
Abaxis initiated with a Hold at Aegis
Aegis analyst Benjamin Haynor initiated Abaxis with a Hold and a $56.50 price target saying the company is potentially attractive but views it as a "show me" story.
08/23/17
BOFA
08/23/17
INITIATION
Target $42
BOFA
Underperform
Abaxis reinstated with an Underperform at BofA/Merrill
BofA/Merrill analyst Derik De Bruin reinstated Abaxis with an Underperform and a $42 price target saying valuation reflects turnaround initiatives while risks remain.
07/26/17
AGIS
07/26/17
NO CHANGE
AGIS
Survery suggests vet diagnostic revenue likely to beat consensus, says Aegis
Aegis analyst Ben Haynor says his survey of 360 vets indicates that the Q2 revenue of animal diagnostic equipment makers IDEXX (IDXX), Abaxis (ABXX), and Heska (HSKA) will probably beat expectations. The analyst found that vet visits rose 4.1% year-over-year last quarter, while pet owners are becoming more willing to spend money on diagnostic services.
08/01/17
AGIS
08/01/17
NO CHANGE
Target $129.5
AGIS
Buy
Heska price target raised to $129.50 from $114.50 at Aegis
Aegis analyst Benjamin Haynor said that following his survey results and Abaxis' (ABAX) report last week, he was "nearly certain" Heska (HSKA) would have a good quarter, which it did, beating consensus EPS estimates for the ninth straight quarter, he noted. The analyst, who said it is clear Heska is "taking share at a nice clip," sees upside to 2018 estimates and raised his price target on the stock to $129.50 from $114.50. Haynor keeps a Buy rating on Heska shares.
SIEN Sientra
$14.03

-0.24 (-1.68%)

04/17/17
04/17/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. ProPetro Holding (PUMP) initiated with a Buy at Tudor Pickering. 2. Canadian Solar (CSIQ) initiated with a Buy at Axiom. 3. Bright Horizons (BFAM) assumed with an Outperform at Credit Suisse. 4. Sientra (SIEN) initiated with a Buy at Lake Street. 5. Himax (HIMX) initiated with an Outperform at Macquarie. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/13/17
WBLR
09/13/17
UPGRADE
WBLR
Outperform
Sientra upgraded to Outperform from Market Perform at William Blair
William Blair analyst Margaret Kaczor upgraded Sientra to Outperform saying the manufacturing approval is "just the tip of the story."
08/28/17
ADAM
08/28/17
INITIATION
Target $14
ADAM
Buy
Sientra initiated with a Buy at Canaccord
Canaccord analyst Kyle Rose initiated Sientra with a Buy rating and $14 price target. The analyst sees Sientra as uniquely positioned to take market share across multiple segments of the U.S. aesthetics industry and for that share to be supported by Sientra's broader product portfolio that includes a focus on breast reconstruction, scar reduction, and the energy-based capital device market.
07/11/17
SPHN
07/11/17
INITIATION
Target $12
SPHN
Overweight
Sientra initiated with an Overweight at Stephens
Stephens initiated Sientra with an Overweight rating and $12 price target.

TODAY'S FREE FLY STORIES

BAYRY

Bayer

$0.00

(0.00%)

15:19
11/20/18
11/20
15:19
11/20/18
15:19
Hot Stocks
Bayer granted FDA orphan designation for Hemophilia A treatment »

Bayer was granted FDA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BILI

Bilibili

$13.68

0.65 (4.99%)

15:19
11/20/18
11/20
15:19
11/20/18
15:19
Options
Bilibili options imply 19.2% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

15:17
11/20/18
11/20
15:17
11/20/18
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XENE

Xenon Pharmaceuticals

$8.18

0.12 (1.49%)

15:16
11/20/18
11/20
15:16
11/20/18
15:16
Hot Stocks
Xenon granted orphan designation for alternating hemiplegia treatment »

Xenon…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

15:16
11/20/18
11/20
15:16
11/20/18
15:16
Technical Analysis
NYSE market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SCG

Scana

$44.14

0.44 (1.01%)

, D

Dominion

$74.55

0.15 (0.20%)

15:12
11/20/18
11/20
15:12
11/20/18
15:12
Hot Stocks
Scana higher as Dominion offers alternate deal plan to South Carolina PSC »

According to a new filing…

SCG

Scana

$44.14

0.44 (1.01%)

D

Dominion

$74.55

0.15 (0.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACHN

Achillion

$2.89

0.11 (3.96%)

15:10
11/20/18
11/20
15:10
11/20/18
15:10
Options
Second day of call buying in Achillion Pharma »

Second day of call buying…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NXRT

NexPoint Residential

$36.26

0.93 (2.63%)

15:06
11/20/18
11/20
15:06
11/20/18
15:06
Hot Stocks
NexPoint Residential VP Matt McGraner buys over $313K in company shares »

NexPoint Residential VP…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMWYY

BMW

$0.00

(0.00%)

, DDAIF

Daimler AG

$0.00

(0.00%)

15:04
11/20/18
11/20
15:04
11/20/18
15:04
Periodicals
Trump plans talks with German car executives, Bloomberg says »

The White House has…

BMWYY

BMW

$0.00

(0.00%)

DDAIF

Daimler AG

$0.00

(0.00%)

VLKAY

Volkswagen

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPS

Gap

$24.91

-0.535 (-2.10%)

15:04
11/20/18
11/20
15:04
11/20/18
15:04
Options
Gap options imply 11.5% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 03

    Mar

D

Dominion

$74.65

0.25 (0.34%)

, SCG

Scana

$44.08

0.38 (0.87%)

15:01
11/20/18
11/20
15:01
11/20/18
15:01
Periodicals
Dominion proposes alternate plan for Scana deal, Bloomberg says »

Bloomberg cites an…

D

Dominion

$74.65

0.25 (0.34%)

SCG

Scana

$44.08

0.38 (0.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USO

United States Oil Fund

$11.27

-0.865 (-7.13%)

15:00
11/20/18
11/20
15:00
11/20/18
15:00
Options
Active trading in US Oil Fund options as crude oil drops 7% »

Active trading in US Oil…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:00
11/20/18
11/20
15:00
11/20/18
15:00
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

HIMX

Himax

$4.05

-0.075 (-1.82%)

14:56
11/20/18
11/20
14:56
11/20/18
14:56
Downgrade
Himax rating change  »

Himax downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 04

    Dec

  • 05

    Dec

14:55
11/20/18
11/20
14:55
11/20/18
14:55
General news
U.S. Durable Goods Preview »

U.S. Durable Goods…

14:55
11/20/18
11/20
14:55
11/20/18
14:55
General news
U.S. Existing Home Sales Preview »

U.S. Existing Home Sales…

14:55
11/20/18
11/20
14:55
11/20/18
14:55
General news
U.S. Michigan Consumer Sentiment Preview »

U.S. Michigan Consumer…

14:55
11/20/18
11/20
14:55
11/20/18
14:55
General news
U.S. Leading Indicators Preview »

U.S. Leading Indicators…

FB

Facebook

$131.60

-0.02 (-0.02%)

14:53
11/20/18
11/20
14:53
11/20/18
14:53
Periodicals
Dashboard to track time wasted on Facebook starts roll out, Venture Beat says »

Facebook has confirmed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

HIMX

Himax

$4.05

-0.075 (-1.82%)

14:52
11/20/18
11/20
14:52
11/20/18
14:52
Downgrade
Himax rating change  »

Himax downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 04

    Dec

  • 05

    Dec

XRT

S&P Retail Index SPDR

$44.32

-1.2 (-2.64%)

14:50
11/20/18
11/20
14:50
11/20/18
14:50
Options
SPDR Retail Trust options are active ahead of Black Friday »

SPDR Retail Trust options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADSK

Autodesk

$122.41

-3.34 (-2.66%)

14:49
11/20/18
11/20
14:49
11/20/18
14:49
Options
Autodesk options imply 12.7% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 26

    Nov

  • 04

    Dec

EQT

EQT Corporation

$16.81

-0.25 (-1.47%)

14:45
11/20/18
11/20
14:45
11/20/18
14:45
Options
EQT Corporation call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCAU

Fiat Chrysler

$15.78

-0.635 (-3.87%)

14:35
11/20/18
11/20
14:35
11/20/18
14:35
Options
Fiat Chrysler put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLDX

Celldex

$0.31

-0.0002 (-0.06%)

14:32
11/20/18
11/20
14:32
11/20/18
14:32
Hot Stocks
Celldex announces launch of Chase Offers »

Cardlytics announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.